177 Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study

作者：Amar U. Kishan, Luca Valle, Holly Wilhalme, Carol Felix, R. Nabong, Javier Casillas, Kevin Flores, Ting Martin, Vinícius Ludwig, Mariko Nakayama, Zachary Ells, Magnus Dahlbom, Michael Lauria, Catherine Meyer, Minsong Cao, Joanne B. Weidhaas, Donatello Telesca, Kristen M. McGreevy, Nicholas G. Nickols, Daniel Karasik, Sophia Parmisano, T. Vincent Basehart, Wayne Brisbane, Leonard S. Marks, Matthew B. Rettig, Robert E. Reiter, Paul C. Boutros, Martin Allen-Auerbach, Johannes Czernin, Michael L. Steinberg, Jérémie Calais · 发表于：Journal of Clinical Oncology · 年份：2025 · DOI：10.1200/jco-25-01553 · 被引用次数：24 · 研究领域：Prostate Cancer Treatment and Research、Prostate Cancer Diagnosis and Treatment、Radiopharmaceutical Chemistry and Applications

PURPOSE Progression after metastasis-directed therapy via stereotactic body radiotherapy (SBRT) for oligorecurrent hormone-sensitive prostate cancer (orHSPC) is common. We aimed to assess whether the addition of neoadjuvant prostate-specific membrane antigen (PSMA)–targeting radioligand therapy to SBRT would improve outcomes. METHODS The LUNAR trial was a single-center, randomized, open-label, controlled phase II trial conducted at the University of California, Los Angeles. Eligible participants had orHSPC as determined by the presence of one to five lesions identified on PSMA positron emission tomography/computed tomography (PET/CT). After stratifying by stage (N1/M1a v M1b) and lesion count (1 v 2-3 v 4-5), we randomly assigned patients 1:1 to receive SBRT to all lesions or two cycles of 177 Lu-PNT2002 (6.8 GBq/cycle, 2 weeks apart) followed by SBRT to all lesions. The primary end point was progression-free survival (PFS), defined by PSMA PET/CT, salvage hormonal therapy, or death. PSMA PET/CT was acquired systematically at prostate-specific antigen progression and/or 12 months after SBRT. All analyses were done in the intention-to-treat population. The study is registered with ClinicalTrials.gov (identifier: NCT05496959 ). RESULTS From September 2, 2022, to November 9, 2023, 92 patients were randomly assigned (SBRT n = 47 and 177 Lu + SBRT n = 45), with 87 evaluable patients (SBRT n = 42 and 177 Lu + SBRT n = 45). At a median follow-up of 22 months, the addition of 177 Lu ...